David Epstein named chief operating officer of Novartis Pharmaceuticals Corporation, reporting to CEO Wayne Yetter. Epstein, who joined Sandoz in 1989 as a new product manager, was previously head of product and customer businesses. That position will be eliminated. Epstein co-chaired the U.S. and Canadian Pharma Steering Committees overseeing the integration of Ciba and Sandoz in 1996. Epstein holds an MBA from Columbia University and was an associate with Booz, Allen and Hamilton before joining Sandoz
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth